arrow_back Back to App

End Drug Price Gouging: Lower Costs for All Americans

This bill aims to lower prescription drug prices by setting maximum prices based on international rates. This means that medications for individuals in federal programs, as well as all other citizens, will not be able to exceed these set limits. Manufacturers who do not comply will face penalties, with collected funds directed towards drug research.
Key points
Establishes maximum prices for prescription drugs to make them more affordable for citizens.
Drug prices will be based on the lowest retail prices in selected countries like Canada, Germany, or the UK.
New rules apply to individuals in Medicare, Medicaid, TRICARE, veteran and federal employee programs, and all other citizens, including the uninsured.
Drug manufacturers selling above the set price will face significant penalties, with funds used for new drug development.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_1753
Sponsor: Sen. Merkley, Jeff [D-OR]
Process start date: 2025-05-14
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

End Price Gouging for Medications Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_1753.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-05-14.

What are the main provisions?

Key points include:

  • Establishes maximum prices for prescription drugs to make them more affordable for citizens.
  • Drug prices will be based on the lowest retail prices in selected countries like Canada, Germany, or the UK.
  • New rules apply to individuals in Medicare, Medicaid, TRICARE, veteran and federal employee programs, and all other citizens, including the uninsured.
  • Drug manufacturers selling above the set price will face significant penalties, with funds used for new drug development.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Merkley, Jeff [D-OR].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health